Parkinson's Disease

Glycation of α-synuclein in Parkinson’s disease 2:02
Glycation of α-synuclein in Parkinson’s disease
Tiago Outeiro • 25 Apr 2023
Extracellular vesicles in Parkinson’s disease 3:00
Extracellular vesicles in Parkinson’s disease
Tiago Outeiro • 25 Apr 2023
ND0612 vs oral immediate-release levodopa/carbidopa in patients with PD and motor fluctuations 3:31
ND0612 vs oral immediate-release levodopa/carbidopa in patients with PD and motor fluctuations
Alberto Espay • 27 Apr 2023
Imaging glymphatic flow in animal models 1:09
Imaging glymphatic flow in animal models
Ian Harrison • 25 Apr 2023
Investigating the glymphatic system in neurodegenerative diseases 1:22
Investigating the glymphatic system in neurodegenerative diseases
Ian Harrison • 25 Apr 2023
Ongoing efforts to improve levodopa-based treatments in Parkinson’s disease 2:34
Ongoing efforts to improve levodopa-based treatments in Parkinson’s disease
Dag Nyholm • 24 Mar 2023
What is the significance of gastrointestinal involvement in Parkinson’s disease? 1:44
What is the significance of gastrointestinal involvement in Parkinson’s disease?
Dag Nyholm • 24 Mar 2023
Novel brain penetrant capsids for Parkinson’s disease gene therapy 2:37
Novel brain penetrant capsids for Parkinson’s disease gene therapy
Todd Carter • 29 Mar 2023
Main treatment targets in Parkinson’s disease clinical research 1:25
Main treatment targets in Parkinson’s disease clinical research
Gennaro Pagano • 5 Apr 2023
Practical guidance for healthcare teams starting patients on LECIG 1:18
Practical guidance for healthcare teams starting patients on LECIG
Dag Nyholm • 24 Mar 2023
What is the future of immunotherapy in Parkinson’s disease? 2:03
What is the future of immunotherapy in Parkinson’s disease?
Gennaro Pagano • 5 Apr 2023
Latest developments in Parkinson’s disease biomarkers 6:10
Latest developments in Parkinson’s disease biomarkers
Andrea Pilotto • 23 Mar 2023
Key questions for cell and gene therapy trials in Parkinson’s disease 2:23
Key questions for cell and gene therapy trials in Parkinson’s disease
Emma Lane • 29 Mar 2023
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease 2:02
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease
Gennaro Pagano • 5 Apr 2023
The patient experience in cell- and gene-therapy trials for Parkinson’s disease 4:43
The patient experience in cell- and gene-therapy trials for Parkinson’s disease
Emma Lane • 29 Mar 2023
Importance of the patient voice in clinical trials 1:13
Importance of the patient voice in clinical trials
Emma Lane • 29 Mar 2023
The content of VJNeurology is intended for healthcare professionals